One-Year Treatment with Galcanezumab in Patients with Chronic Migraine: Results from the Open-Label Phase of the REGAIN Study

被引：0
|
作者：
Detke, Holland [1 ]
Pozo-Rosich, Patricia [2 ,3 ]
Reuter, Uwe [4 ]
Dolezil, David [5 ]
Li, Lily Q. [1 ]
Wang, Shufang [1 ]
Aurora, Sheena K. [1 ]
机构：
[1] Eli Lilly & Co, Indianapolis, IN 46285 USA
[2] Vall dHebron Univ Hosp, Barcelona, Spain
[3] Univ Autonoma Barcelona, Barcelona, Spain
[4] Charite Med Univ Berlin, Berlin, Germany
[5] DADO MEDICAL Sro, Prague, Czech Republic
来源：
NEUROLOGY | 2019年 / 92卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P2.10-010
引用
收藏
页数：3
相关论文
共 50 条
  • [1] ONE-YEAR TREATMENT WITH GALCANEZUMAB IN PATIENTS WITH CHRONIC MIGRAINE: RESULTS FROM THE OPEN-LABEL PHASE OF THE REGAIN STUDY
    Detke, H. C.
    Li, L. Q.
    Wang, S.
    Aurora, S. K.
    CEPHALALGIA, 2018, 38 : 149 - 149
  • [2] Long-term treatment with galcanezumab in patients with chronic migraine: results from the open-label extension of the REGAIN study
    Pozo-Rosich, Patricia
    Detke, Holland C.
    Wang, Shufang
    Dolezil, David
    Li, Lily Q.
    Aurora, Sheena K.
    Reuter, Uwe
    CURRENT MEDICAL RESEARCH AND OPINION, 2022, 38 (05) : 731 - 742
  • [3] Galcanezumab in patients with episodic migraine: results from the open-label period of the phase 3 PERSIST study
    Zhou, Jiying
    Zhong, Lianmei
    Chowdhury, Debashish
    Skorobogatykh, Kirill
    Luo, Guogang
    Yang, Xiaosu
    Zhang, Mingjie
    Sun, Lingli
    Liu, Hui
    Qian, Chenxi
    Yu, Shengyuan
    JOURNAL OF HEADACHE AND PAIN, 2023, 24 (01):
  • [4] Galcanezumab in patients with episodic migraine: results from the open-label period of the phase 3 PERSIST study
    Jiying Zhou
    Lianmei Zhong
    Debashish Chowdhury
    Kirill Skorobogatykh
    Guogang Luo
    Xiaosu Yang
    Mingjie Zhang
    Lingli Sun
    Hui Liu
    Chenxi Qian
    Shengyuan Yu
    The Journal of Headache and Pain, 24
  • [5] Galcanezumab in patients with treatment-resistant migraine: results from the open-label phase of the CONQUER phase 3 trial
    Detke, H. C.
    Reuter, U.
    Lucas, C.
    Dolezil, D.
    Hand, A.
    Tockhorn-Heidenreich, A.
    Stroud, C.
    Aurora, S. K.
    EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 298 - 298
  • [6] One-year results from an open-label study of donidalorsen in patients with hereditary angioedema
    Bordone, Laura
    Newman, Kenneth B.
    Deng, Yiwen
    Alexander, Veronica J.
    Riedl, Marc A.
    Schneider, Eugene
    Cohn, Danny M.
    ALLERGY AND ASTHMA PROCEEDINGS, 2024, 45 (01)
  • [7] One-year results of an open-label study on antiproteinuric effect of benidipine in elderly patients with chronic kidney disease
    Tomino, Yasuhiko
    Shimizu, Yoshio
    Hamada, Chieko
    Kurusu, Atsushi
    Ohsawa, Isao
    Suzuki, Yusuke
    Tsuge, Toshinao
    Io, Hiroaki
    Kobayashi, Noriyoshi
    Takeda, Yukihiko
    Asanuma, Katsuhiko
    Tanaka, Yuichi
    Suzuki, Hitoshi
    Nakata, Jun-ichiro
    Takara, Katsuhiko
    Horikoshi, Satoshi
    JOURNAL OF NEPHROLOGY, 2011, 24 (06) : 756 - 763
  • [8] A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine
    Angelo Camporeale
    David Kudrow
    Ryan Sides
    Shufang Wang
    Annelies Van Dycke
    Katherine J. Selzler
    Virginia L. Stauffer
    BMC Neurology, 18
  • [9] A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine
    Camporeale, Angelo
    Kudrow, David
    Sides, Ryan
    Wang, Shufang
    Van Dycke, Annelies
    Selzler, Katherine J.
    Stauffer, Virginia L.
    BMC NEUROLOGY, 2018, 18
  • [10] Efficacy Results from an Open-Label Safety Study of Galcanezumab in Patients with Episodic or Chronic Cluster Headache
    Gaul, C.
    Riesenberg, R.
    Stroud, C.
    Dong, Y.
    Oakes, T. Myers
    CEPHALALGIA, 2021, 41 (1_SUPPL) : 234 - 235
12345